Share
(Investorideas.com
Newswire) a go-to platform for big investing ideas, including AI,
biotech stock issues, news, and trading alerts for Lunai Bioworks (NASDAQ: LNAI), an AI-driven life sciences company.
The stock makes the Nasdaq top percentage gainer list following
news, currently trading at $0.6080, up 0.2065, gaining 51.69% on a
volume of over 200 million shares.
Lunai Bioworks (NASDAQ: LNAI) is an AI-driven life sciences company advancing drug discovery
through its integrated platform. The Company combines clinical data,
machine learning, and in vivo validation to identify disease biology
and develop precision therapeutics. Lunai is focused on central
nervous system diseases and oncology, with a mission to reduce
development timelines and improve clinical success rates.
Lunai Bioworks just announced it has executed a binding $20 million
strategic transaction to acquire blood-brain barrier (BBB) delivery
technology and central nervous system (CNS) Alzheimer’s drug assets
from the Clemann Group, SAS, or its assignee.
The transaction is structured as Series B Convertible Preferred at a
fixed conversion price of $1.50 per share, subject to a 19.9%
beneficial ownership limitation. The structure contains no variable
pricing or reset provisions, strengthening the company’s equity
position while remaining NASDAQ compliant.
This acquisition brings a delivery platform to Lunai that addresses
one of the most significant bottlenecks in CNS drug development:
effectively transporting therapeutics into the brain. The underlying
chemistry allows compounds to cross the blood-brain barrier, remain
inactive in the body, and then activate specifically inside the
brain. The platform’s mechanism of action targets pathways central
to acetylcholinesterase modulation in the brain, which are broadly
implicated in neurological disease.
What makes this important is that it directly strengthens Lunai’s
CNS Alzheimer’s pipeline by pairing precise biological target
identification with a proven delivery method. At the same time, it
expands the company’s ability to develop next-generation treatments
across a broad range of CNS disorders where traditional drugs
struggle to penetrate the brain effectively, offering the potential
for improved safety and efficacy.
“This is a step-change in our capabilities,” said David Weinstein,
CEO of Lunai Bioworks. “We are now combining the ability to
identify the right biology with a validated mechanism to deliver
therapies directly into the brain. This has profound implications
for how we treat Alzheimer’s and other complex CNS diseases that
have historically been unreachable.”
Full News
Research AI and tech stocks at Investorideas.com
https://www.investorideas.com/TSS/stock_list.asp
About Investorideas.com – Big Investing Ideas
Investorideas.com
is the go-to platform for big investing ideas. From breaking stock
news to top-rated investing podcasts, we cover it all. Our original
branded content includes podcasts such as Exploring Mining, Cleantech,
Crypto Corner, Cannabis News, and the AI Eye. We also create free
investor stock directories for sectors including mining, crypto,
renewable energy, gaming, biotech, tech, sports and more. Public
companies within the sectors we cover can use our news publishing and
content creation services to help tell their story to interested
investors. Paid content is always disclosed.
Learn more about our news, PR and social media, podcast and content
services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Follow us on X @investorideas @stocknewsbites
Follow us on
Facebook
https://www.facebook.com/Investorideas
Follow us on YouTube
https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800 665 0411
Investorideas is a digital publisher of third party sourced news,
articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of
stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investing involves risk and possible losses. Contact management and IR
of each company directly regarding specific questions.
